FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma

2021345 citationsJournal Articlegreen Open Access

Authors

Good health and well-being

Published in: Annals of Oncology

Volume 32, Issue 5, pp. 609-619

Field-Weighted Citation Impact: 38.90